EP1233746A1 - Tampon empechant les infections cutanees par candida albicans - Google Patents

Tampon empechant les infections cutanees par candida albicans

Info

Publication number
EP1233746A1
EP1233746A1 EP00981984A EP00981984A EP1233746A1 EP 1233746 A1 EP1233746 A1 EP 1233746A1 EP 00981984 A EP00981984 A EP 00981984A EP 00981984 A EP00981984 A EP 00981984A EP 1233746 A1 EP1233746 A1 EP 1233746A1
Authority
EP
European Patent Office
Prior art keywords
skin
occlusive
article
buffering
mucous membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00981984A
Other languages
German (de)
English (en)
Inventor
Bo Runeman
Jan Faergemann
Olle LARKÖ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essity Hygiene and Health AB
Original Assignee
SCA Hygiene Products AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCA Hygiene Products AB filed Critical SCA Hygiene Products AB
Publication of EP1233746A1 publication Critical patent/EP1233746A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

  • the present application relates to using a substance capable of buffering within the pH range 2.0 - 5.5, for preparing a skin-occlusive or mucous membrane-occlusive article for preventing skin irritations and lesions caused by Candida albicans.
  • a substance capable of buffering within the pH range 2.0 - 5.5 for preparing a skin-occlusive or mucous membrane-occlusive article for preventing skin irritations and lesions caused by Candida albicans.
  • absorbent articles such as diapers and sanitary napkins, wound dressings, such as bandages surgical tapes and plasters, gloves, prostheses and indwelling catheters.
  • Candida albicans may constitute a major problem in connection with using skin-occlusive, mucous membrane-occlusive and absorbent articles such as diapers, pantyliners, sanitary napkins and wound dressings.
  • Candida albi- cans has been found to correlate with severity of diaper dermatitis (Benjamin L, Pediatrician 1987, suppl. 1, p. 21 - 26).
  • There are investigators that give C. Albicans a primary causative role in some expressions of diaper dermatitis (Leyden J and Kligman AM, Arch. Dermatol. 1978, vol 114, p. 56 - 59).
  • pH appears to be a major source of confusion and contradiction in the context of Candida ecology.
  • Candida carriage in vivo can occur readily over a broad range of pH. pH may be a factor of significance in the pathological status of C. albicans in vivo, but it does not exert its influence by affecting growth of the fungus, i.e. the rate of increase of its biomass (Odds FC, Candida and Candidosis. A review and bibliography. 2 nd ed. 1988, Bailliere Tindall).
  • Dimorphism the ability of C. albicans to exist in a blastospore and a filamentous form, is reported to be influenced by pH (Buffo et al., Mycopathologia, vol. 85 (1984), p.
  • WO 98/57677 and EP 0 202 126 both disclose that a neutral or a slightly alkaline pH in connection with using absorbent articles may lead to skin irritation and problems with odorous substances. According to the documents these problems are caused by Upases and proteinases present on the skin and the problems can be overcome by decreasing the pH of the absorbent article. The documents do not give any particular information about problems caused by Candida or how to reduce the virulence of Candida albicans.
  • a skin-occlusive or mucous membrane-occlusive article such as an absorbent article (a diaper, a sanitary napkin, a pantyliner or a wound dressing, such as a bandage), a plaster, a surgical tape, said article containing a pharmaceutically acceptable non-toxic and non-irritating substance capable of buffering within the pH range 2.0 - 5.5, is used to for preventing skin irritations and lesions caused by Candida albicans.
  • the present invention relates to using an ingredient capable of buffering within the pH range 2.0 - 5.5, for preparing a skin-occlusive article for preventing skin irritations and lesions caused by Candida albicans.
  • Any pharmaceutically acceptable, non-toxic and non-irritating ingredient capable of buffering within the specified range can be used.
  • suitable buffering ingredients are superab- sorbent particles showing a level of neutralisation within the range of 20 - 50 %, and pharmaceutically acceptable, non-toxic and non-irritating buffering solutions, such as organic salt buffering solutions, for example an acetate buffer or a citrate buffer.
  • the buffering solution can be directly added to the skin-occlusive or mucous membrane-occlusive article.
  • a pharmaceutically acceptable gel con- taining the buffering solution can be added.
  • suitable gels include gels normally used for pharmaceutical purposes, such as agarose.
  • an acid buffering substance according to the present invention is added to a skin- occlusive article.
  • skin-occlusive article or “mucous membrane-occlusive article” relates to an article, which is intended to cover the skin or mucous membranes of a person.
  • a skin-occlusive article or mucous membrane- occlusive article according to the present invention can be an absorbent article, such as a diaper, a sanitary napkin, a pantyliner or a wound dressing, a surgical tape, a plaster, gloves, prostheses or indwelling catheters. It is not critical for the invention how the acid buffering substance is added, and accordingly it can be added to the skin-occlusive article in many different ways.
  • Examples of suitable methods for adding the acid buffering substance to the skin occlusive article are administration of a solution containing the acid buffering substance, or administration of said substance as a powder or gel.
  • the administration can be carried out in connection with manufacturing said article or after said article has been manufactured.
  • the term "pharmaceutically acceptable antifungal agent” relates to compounds normally used to treat Candida infections, such as imidazole derivatives, nystatin and ciclopirox olamine. These compounds are added to the skin- occlusive or mucous membrane-occlusive article in amounts corresponding to common therapeutical doses.
  • Figure 1 shows an example of a diaper to which an acid buffering substance can be added in accordance with the invention
  • Figure 2 discloses the natural distribution of skin surface pH on volar forearms in 15 females. The observations are mean values of left and right arm;
  • Figure 3 presents a diagram showing pH development of patch sites before, during and after wearing a patch buffered with an acid buffering substance and a regular reference patch;
  • Table I presents results from visual assessment of skin reaction to Candida albicans infection.
  • Table II shows growth of Candida albicans 24 hours after inoculation.
  • the diaper 100 disclosed in figure 1 comprises a liquid-permeable outer layer 1, for example made of a fibre fabric or a perforated plastic film, a liquid-impermeable outer layer 2, for example made of a plastic film or a hydrophobic fibre fabric, and finally an absorbent body 3 enclosed between the outer layers 1, 2.
  • a liquid-permeable outer layer for example made of a fibre fabric or a perforated plastic film
  • a liquid-impermeable outer layer 2 for example made of a plastic film or a hydrophobic fibre fabric
  • the diaper is intended to surround the lower part of the trunk of the wearer like a pair of absorbing pants. It is therefore designed with two end parts 4, 5 as well as a narrower crutch part 6 between the end parts, which when the diaper is used is intended to be arranged in the crutch of the wearer between the legs.
  • adhesive flaps 7 are arranged close to the rear waist edge 8. Upon use, the adhesive flaps are fastened to the front part 5 of the diaper, close to the front waist edge 9, in order to hold the diaper together around the waist of the wearer.
  • the diaper according to figure 1 comprises pretightened elastic means 10, which may consist of elastic strings, elastic threads, elastic foam or another suitable material.
  • the elastic means 10 are, for the sake simplicity, shown in outstreched condition. However, as soon as the stretching ceases they contract and form elastic bands in the diaper.
  • the absorbent body 3 in the example shown in figure 1 is formed by two layers 11, 12, an upper liquid-receiving layer 11 and a lower layer 12 which spreads and distributes the liquid.
  • the upper liquid-receiving layer must quickly be able to receive a large amount of liquid within a short amount of time, i.e. have a higher instantaneous liquid absorption capability, but the lower storage and distribution layer 12 must have a high liquid distribution capability and be able to drain liquid out from the receiving layer 11 and distribute this liquid in the storage and distribution layer 12.
  • the differences between the layers 11, 12 can be accomplished by density differences. A more compressed fibre structure distributes the liquid better than a corresponding fibre structure having a lower density.
  • Such a low-density structure has a higher instantaneous liquid absorption capability and a lower distribution capability due to its larger pore size.
  • Different absorption capabilities can also be achieved by using different fibre structures having different characteristics.
  • chemically produced cellulose fluff pulp shows better distribution characteristics compared to, for instance, mechanically or chemi-thermomechanically produced pulp, such as chemi-thermomechanical pulp (CTMP).
  • CMP chemi-thermomechanical pulp
  • a fibre structure containing chemically stiffened cellulose fibres shows a higher instantaneous liquid absorption ability but a lower d stribution ability compared to conventional chemical pulp.
  • Other materials suitable as receiving layers 11 can be a wadding of natural fibres or a fluffy nonwoven material.
  • a partially neutralised superabsorbent is admixed in the upper liquid-receiving layer 11 of the absorbent body 3.
  • This superabsorbent act as a acid buffering substance in accordance with the present invention.
  • a conventional superabsorbent is admixed in the lower liquid storage and distribution layer 12 of the absorbent body. It is advantageous to put a conventional super- absorbent in the lower liquid storage layer 12, because a conventional superabsorbent has a higher total absorption capacity compared to a partially neutralised and pH-regulating superabsorbent.
  • the invention also comprises other embodiments of the absorption body.
  • the absorbent body may contain both partially neutralised superabsorbents and conventional superabsorbents, and both the superabsorbents can be equally distributed in both the upper and lower absorbent layers.
  • both the superabsorbents can be equally distributed in both the upper and lower absorbent layers.
  • the superabsorbent material also acts as a pH-regulating substance in accordance with the present invention.
  • the experimental patches were made of common diaper materials and punched out as circular disks with a diameter of 70 mm.
  • the outer side of polyethylene and the inner side (that will be placed towards the skin) of nonwoven polypropylene were glued together with a 10 mm edge around the inner circular core of 50 mm diameter.
  • the inner core consisted of approximately 0.85 g cellulose pulp and approximately 0.15 g of superabsorbent polymer (IM 7100 and E127/97, Clairant GmbH, DE).
  • the superabsorbent polymer was a polyacrylic acid, which was adjusted to either pH 4.5 or 6.0. It acts as a strong buffering system. 10 4 cells per ml C. albicans were suspended in a physiological saline solution.
  • the C. albicans strain used was type H29, kindly provided by Professor Lars Edebo, Department of Microbiology, Sahlgrenska University Hospital, Goteborg, SE. Cells were grown on Sabouraud's glucose agar at 37°C for 24 hours before use.
  • a modification of the Williamson- Kligman scrub technique was used for assessment of the resident skin microflora and the added C. albicans.
  • a stainless steel ring with an internal diameter of 2.6 cm and covering a skin area of 5.5 cm was used.
  • One millimetre of sterile 0.075 M phosphate buffer (pH 7.9) containing 0.1% Triton X-100 was poured into the ring, and the skin was gently rubbed with a blunt sterile glass rod for one minute and the fluid was removed with a Pasteur pipette (Faerge- mann J. Mapping the Fungi of the Skin. Handbook of Non-invasive Methods and the Skin, chapter 10.2, CRC Press, 1995).
  • Serial dilutions were performed in PBS and samples from the dilutions were plated out. Plates were incubated at 37°C and read after 48h.
  • the paired t test was used to test for statistical significance between pH differences, differences in number of Candida organisms. The differences in observed skin le- sions were tested by a sign test.
  • the skin surface pH of the 15 volunteers was measured at the start and varied be- tween 4.5 and 6.0.
  • the mean value was 5.2.
  • the results are shown in figure 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne l'emploi d'un ingrédient à effet tampon dans une plage de pH compris entre 2,0 et 5,5 pour la réalisation d'un article occlusif pour la peau ou occlusif par membrane muqueuse qui protège contre les irritations cutanées et évite les lésions provoquées par Candida albicans. Ces articles absorbants peuvent prendre des formes diverses: couches, protège-slip, serviettes hygiéniques, pansements divers, sparadraps chirurgicaux et emplâtres, gants, prothèses et sondes implantées à demeure.
EP00981984A 1999-12-02 2000-11-06 Tampon empechant les infections cutanees par candida albicans Withdrawn EP1233746A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904387A SE521431C2 (sv) 1999-12-02 1999-12-02 Användning av en pH-buffrande substans för att förhindra hudinfektioner orsakade av Candida Albicans
SE9904387 1999-12-02
PCT/SE2000/002165 WO2001039582A1 (fr) 1999-12-02 2000-11-06 Tampon empechant les infections cutanees par candida albicans

Publications (1)

Publication Number Publication Date
EP1233746A1 true EP1233746A1 (fr) 2002-08-28

Family

ID=20417954

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00981984A Withdrawn EP1233746A1 (fr) 1999-12-02 2000-11-06 Tampon empechant les infections cutanees par candida albicans

Country Status (13)

Country Link
EP (1) EP1233746A1 (fr)
JP (1) JP2003515544A (fr)
KR (1) KR20020060249A (fr)
AU (1) AU778633B2 (fr)
BR (1) BR0016005A (fr)
CA (1) CA2392102A1 (fr)
CO (1) CO5251413A1 (fr)
MX (1) MXPA02005211A (fr)
PL (1) PL355410A1 (fr)
RU (1) RU2002117294A (fr)
SE (1) SE521431C2 (fr)
SK (1) SK7882002A3 (fr)
WO (1) WO2001039582A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630152B2 (en) 1999-04-07 2003-10-07 Shen Wei (Usa), Inc. Aloe vera glove and manufacturing method
US6274154B1 (en) 1999-04-07 2001-08-14 Belle L Chou Aloe Vera glove and manufacturing method
EP1354586A1 (fr) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH Utilisation de dérivés de l'hydroxypyridone pour soigner des plaies
US20030204893A1 (en) * 2002-05-02 2003-11-06 Chou Belle L. Elastomeric flexible article and manufacturing method
US9757285B2 (en) 2011-03-07 2017-09-12 Edgewell Personal Care Brands, Llc Absorbent article including a buffer composition
DE102011106046A1 (de) 2011-06-30 2013-01-03 Paul Hartmann Ag Wundversorgungsprodukt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794034A (en) * 1973-02-27 1974-02-26 J Jones Odor reductant body waste pad
PH23760A (en) * 1985-05-15 1989-11-03 Procter & Gamble Disposable absorbent articles
US4842593A (en) * 1987-10-09 1989-06-27 The Procter & Gamble Company Disposable absorbent articles for incontinent individuals
AU6044094A (en) * 1994-01-17 1995-08-01 Carlo Alfredo Graziani Napkin with buffer substance
SE511838C2 (sv) * 1997-06-17 1999-12-06 Sca Hygiene Prod Ab Minskning av oönskade sidoeffekter vid användning av absorberande alster med hjälp av pH-styrning
JP2001520188A (ja) * 1997-10-22 2001-10-30 ポニカウ，ジェンス 粘膜組織の炎症を治療および予防するための方法ならびに物質
EP1061964B2 (fr) * 1998-03-12 2009-10-28 The Procter & Gamble Company Agents actifs donneurs de protons contenus dans des articles absorbants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0139582A1 *

Also Published As

Publication number Publication date
KR20020060249A (ko) 2002-07-16
JP2003515544A (ja) 2003-05-07
CO5251413A1 (es) 2003-02-28
RU2002117294A (ru) 2004-01-27
SE521431C2 (sv) 2003-11-04
CA2392102A1 (fr) 2001-06-07
PL355410A1 (en) 2004-04-19
SE9904387L (sv) 2001-06-03
BR0016005A (pt) 2002-07-30
SK7882002A3 (en) 2002-12-03
AU1906301A (en) 2001-06-12
WO2001039582A1 (fr) 2001-06-07
MXPA02005211A (es) 2002-12-09
SE9904387D0 (sv) 1999-12-02
AU778633B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US5827247A (en) External incontinence device and vapor-absorptive adhesive compositions
US20100151032A1 (en) Silver and Zinc Containing Body Care Agent
DE60126506T2 (de) Verbände zur behandlung von exsudierenden wunden
EP3305335A1 (fr) Pansement de plaie ou peau composé multifonctionnel comme substitut de peau régénératif
CA2313858A1 (fr) Films microporeux comprenant des fibres de flocage
EP2209502B1 (fr) Articles de soin d'hygiène personnelle contenant des peptides à auto-assemblage
KR20010085581A (ko) 피부 건강을 유지하거나 또는 개선시키는 흡수 용품
US20060062854A1 (en) Hydrogel having anti-microbial properties
AU9470798A (en) Product and preparation containing lactic acid bacteria
CN103768647B (zh) 一种中药保健吸收性物品
MXPA02000879A (es) Articulo absorbente el cual mantiene la temperatura de la piel cuando esta mojado.
EP3441054B1 (fr) Dispositif pour le traitement d'une infection fongique vaginale
JP6290184B2 (ja) 創傷ドレッシング
AU778633B2 (en) Use of a buffer to prevent candida albicans infections on the skin
US6559353B1 (en) Treated disposable articles for reducing skin breakdown
US20090076474A1 (en) Absorbent articles comprising an aglycone derivable from an iridoid glycoside
EP1220665A1 (fr) Utilisation d'acides de houblon pour inhiber la croissance du staphylocoque dore
JP2004255165A (ja) 吸収性物品
Williams The role of Sterigel hydrogel wound dressing in wound debridement
James Wound dressings in accident and emergency departments
CN118356525A (zh) 一种含有5-氨基乙酰丙酸的液体创可贴
CN106456421A (zh) 包含微生物抑制组分的吸收性产品
Shai et al. Dressing materials
KR20070057884A (ko) 외분비단백질의 생산을 억제하기 위한 비-흡수 및 흡수용품
Bhopal et al. ACOMPARATIVE STUDY OF THE EFFICACY AND COST-EFFECTIVENESS OF OCCLUSIVE VERSUS CONVENTIONAL DRESSING IN THE TREATMENT OF OPEN WOUNDS AND ULCERS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041110